| Literature DB >> 2727988 |
Y Saijo1, N Kumano, S Suzuki, S Koinumaru, S Sugawara, K Oizumi, M Motomiya.
Abstract
A VP-16-resistant subline was established from THP-1 human monocytic leukemia cells by subculturing in stepwise increasing concentrations of the drug. The resistant cells (THP-1/E) were capable of sustaining continuous growth in 1.0 microgram/ml VP-16. The 50% inhibition dose (IC50) was 1.4 micrograms/ml or a 35-fold of the parent cells. A more than 18-fold IC50 was also obtained with teniposide (VM-26). However, no substantial cross-resistance was observed with 5 other antineoplastic drugs, IC50 values being limited below several times of THP-1.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2727988 DOI： 10.1620/tjem.157.215
Source DB: PubMed Journal: Tohoku J Exp Med ISSN： 0040-8727 Impact factor: 1.848